The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

Internal political squabbles — and the fallout from a global backlash to inflation, immigration and ruling elites — are hobbling Germany and France. By Jim Tankersley and Aurelien Breeden ...

The president-elect’s call for Taiwan to spend more on its own defense and his complaints about its semiconductor dominance may herald a tenser relationship. By Chris Buckley and Amy Chang ...

Why are the two often so disconnected? And what role can technology play in integrating them? A new CMS accountable care program aims to drive progress, and one expert explains what it means for ...

Nov. 1, 2024 — Microplastics have been steadily increasing in freshwater environments for decades and are directly tied to rising global plastic production since the 1950s, according to a new ...

Nov. 7, 2024 — Plastic pollution exacerbates the impacts of all planetary boundaries, including climate change, ocean acidification and biodiversity loss, a new paper shows. Ahead of the final ...